China Biologic Products Holdings, Inc. (CBPO): Price and Financial Metrics

China Biologic Products Holdings, Inc. (CBPO)

Today's Latest Price: $118.95 USD

0.20 (0.17%)

Updated Nov 27 1:00pm

Add CBPO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 115 in China

See all "A" rated Strong Buy stocks

CBPO Stock Summary

  • For CBPO, its debt to operating expenses ratio is greater than that reported by just 0.52% of US equities we're observing.
  • CBPO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 10.48% of US stocks.
  • In terms of volatility of its share price, CBPO is more volatile than merely 0.16% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to China Biologic Products Holdings Inc are AAON, TTGT, HMSY, EVR, and IRMD.
  • CBPO's SEC filings can be seen here. And to visit China Biologic Products Holdings Inc's official web site, go to

CBPO Stock Price Chart Interactive Chart >

Price chart for CBPO

CBPO Price/Volume Stats

Current price $118.95 52-week high $119.27
Prev. close $118.75 52-week low $97.91
Day low $118.08 Volume 222,800
Day high $119.27 Avg. volume 113,214
50-day MA $114.21 Dividend yield N/A
200-day MA $109.77 Market Cap 4.68B

China Biologic Products Holdings, Inc. (CBPO) Company Bio

China Biologic Products engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in China. The company is based in Beijing, the China.

CBPO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$118.95$152.85 29%

We started the process of determining a valid price forecast for China Biologic Products Holdings Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that China Biologic Products Holdings Inc ranked in the 52th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for China Biologic Products Holdings Inc ended up being:

  • Interest coverage, a measure of earnings relative to interest payments, is 327.49 -- which is good for besting 98.65% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 0.05% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • CBPO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 55.86% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as CBPO, try LMAT, SNY, ACIU, EGRX, and UNH.

CBPO Latest News Stream

Event/Time News Detail
Loading, please wait...

CBPO Latest Social Stream

Loading social stream, please wait...

View Full CBPO Social Stream

Latest CBPO News From Around the Web

Below are the latest news stories about China Biologic Products Holdings Inc that investors may wish to consider to help them evaluate CBPO as an investment opportunity.

Update on China Biologic Products Q2 earnings

China Biologic Products ([[CBPO]] -1.9%) Q2 reports total sales of $111.1M (-18.1% Y/Y).Gross profit decreased by 16.0% to $76.4M.Income from operations decreased by 11.4% to $42.7M from $48.2M last year.Non-GAAP adjusted net income decreased 10.9% to $43.4M.Non-GAAP EPS of $1.11, misses consensus.In April 2020, the company received approval from the Health...

Seeking Alpha | August 18, 2020

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2020 Results - Earnings Call Transcript

China Biologic Products Holdings, Inc. (CBPO) Q2 2020 Results Earnings Conference Call August 18, 2020, 07:30 AM ET Company Participants Philip Lisio - The Foote Group Joseph Chow - Chairman and Chief Executive Officer Ming Yin - Senior Vice President Ming Yang - Chief Financial Officer Conference Call Participants Jason...

SA Transcripts on Seeking Alpha | August 18, 2020

5 Profitable Companies With a Margin of Safety

Comcast makes the list Continue reading...

Yahoo | July 13, 2020

5 Health Care Stocks Boosting Earnings

Biogen tops the list Continue reading...

Yahoo | June 30, 2020

China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan") to China Biologic, which attempts to terminate the cooperation between China Biologic and Xinjiang Deyuan, and urges Xinjiang Deyuan to cure its breaches and continue to perform its obligations under its cooperation agreement with China Biologic. In addition, the Company announced that, through the lawsuits it previously filed against Xinjiang Deyuan, the Company is seeking monetary claims totaling over RMB460 million and has obtained judicial freezing of certain s...

Yahoo | June 29, 2020

Read More 'CBPO' Stories Here

CBPO Price Returns

1-mo 2.36%
3-mo 12.70%
6-mo 8.14%
1-year 2.01%
3-year 42.30%
5-year -1.29%
YTD 2.21%
2019 53.31%
2018 -3.63%
2017 -26.74%
2016 -24.53%
2015 111.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1337 seconds.